Detail akcie Fate Therapeutics online

Business Summary: Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Its product candidates under development include FT819, FT522, FT829, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT522 is its first iPSC-derived CAR NK cell product candidate that incorporates its novel Alloimmune Defense Receptor (ADR) technology.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Fate Therapeutics Inc revenues decreased 15% to $1.6M. Net loss decreased 22% to $37.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Other general & Administrative Expenses decrease of 34% to $10.3M (expense), Stock-based Compensation in R&D decrease of 32% to $3.9M (expense).